MedAcuity and Haply Robotics have entered into a strategic partnership to drive forward innovation in precision haptics for medical and robotic technologies. By combining Haply's pioneering haptic interface solutions with MedAcuity's expertise in regulatory-grade software development, the collaboration will focus on creating next-generation teleoperation systems designed for surgical, diagnostic, and simulation use. The partnership aims to deliver real-time, high-accuracy tactile feedback systems that enhance control, safety, and performance across remote medical and robotic applications.
MedAcuity, a leading software engineering company specialising in complex medical and robotic systems, has announced a strategic partnership with Montréal-based Haply Robotics, a global innovator in haptic and robotic interface technologies. Together, the two firms will accelerate the development of advanced teleoperated systems that unite precision engineering with state-of-the-art haptic feedback, transforming the landscape of remote healthcare, simulation, and training experiences.
The partnership integrates Haply's industry-leading technologies--including the award-winning Inverse3X and MinVerse devices--with MedAcuity's depth of knowledge in software architecture, systems integration, and regulatory-compliant development. By fusing cutting-edge tactile technologies with robust, safety-critical software, the collaboration will deliver systems designed to optimise operator control, fidelity, and reliability in high-stakes scenarios.
"This collaboration represents a natural alignment of strengths," said Dennis Fuccione, President of MedAcuity. "Haply Robotics is at the forefront of human machine interaction, and together, we are poised to push the boundaries of what's possible in remote robotic control and medical device innovation."
"Partnering with MedAcuity allows us to bring our advanced haptic technologies into new domains where precision and reliability are critical," said Colin Gallacher, President of Haply Robotics. "Their proven track record in regulated medical and robotic systems complements our mission to deliver intuitive, tactile experiences that elevate human control in remote environments. Together, we're enabling a new standard for human machine interaction."
Under this collaboration, the companies will jointly develop a portfolio of applications encompassing robotic-assisted surgery, remote diagnostics, and immersive simulation training. Each solution will be built with an emphasis on providing real-time, high-fidelity tactile feedback to enhance user precision, responsiveness, and confidence.
As industries increasingly demand more intuitive and responsive human–robot interfaces--particularly within telemedicine, defence, and industrial automation--the MedAcuity–Haply partnership is well-positioned to lead the next phase of innovation in haptic and teleoperated technologies.
source:newsreleases.co.uk
Antengene reveals ATG-022 clinical data at ESMO 2025
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Viatris acquires Aculys Pharma including certain development and commercialisation rights
AstraZeneca expands Texas facility with USD445m investment to boost Lokelma production
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress